Data-quality flags on Kazakhstan
HIV tests performed with the result returned to the person, 2020 (PEPFAR Panorama Spotlight). The value moved from 283,495 in 2019 to 1,187 in 2020, a change of more than threefold in a single year. The move from 283,495 to 1,187 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2019 and 2020 are not comparable. Check the figures by reporting organisation before reading a trend across 2019 and 2020.
Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS), 2020 (PEPFAR Panorama Spotlight). The value moved from 729 in 2019 to 158 in 2020, a change of more than threefold in a single year. The move from 729 to 158 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2019 and 2020 are not comparable. Check the figures by reporting organisation before reading a trend across 2019 and 2020.
People receiving PrEP, 2024 (PEPFAR Panorama Spotlight). The value moved from 235 in 2023 to 1,410 in 2024, a change of more than threefold in a single year. The move from 235 to 1,410 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2023 and 2024 are not comparable. Check the figures by reporting organisation before reading a trend across 2023 and 2024.
Sources of the figures for Kazakhstan
| Source | Type | Rows | Indicators | Years | Read from | Retrieved |
|---|---|---|---|---|---|---|
| UNICEF HIV/AIDS dataset | Modelled estimate | 1,344 | 3 | 2010–2025 | sdmx.data.unicef.org | 2026-10-20 |
| UNAIDS AIDSinfo | Programme record | 611 | 25 | 2000–2024 | aidsinfo.unaids.org | 2026-10-20 |
| WHO Global Health Observatory | Modelled estimate | 239 | 11 | 2000–2025 | ghoapi.azureedge.net | 2026-10-12 |
| WHO Global Tuberculosis Programme | Programme record | 171 | 17 | 2000–2024 | extranet.who.int | 2026-10-16 |
| PEPFAR results by province | Programme record | 122 | 7 | 2016–2025 | data.pepfar.gov | 2026-10-12 |
| UNAIDS Global AIDS Monitoring expenditure database | Expenditure account | 114 | 16 | 2015–2024 | hivfinancial.unaids.org | 2026-10-12 |
| ForeignAssistance.gov | Expenditure account | 68 | 5 | 2003–2026 | foreignassistance.gov | 2026-10-29 |
| OECD Creditor Reporting System | Expenditure account | 67 | 3 | 2002–2024 | sdmx.oecd.org | 2026-10-12 |
| PEPFAR results by funding agency and province | Programme record | 62 | 4 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| World Bank Open Data | Modelled estimate | 51 | 2 | 2000–2025 | api.worldbank.org | 2026-10-12 |
| IATI, through d-portal | Expenditure account | 46 | 3 | 2003–2026 | d-portal.org | 2026-10-12 |
| PEPFAR testing by modality | Programme record | 46 | 6 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR Panorama Spotlight | Programme record | 43 | 6 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| WHO Europe Health for All database | Programme record | 40 | 2 | 2000–2019 | dw.euro.who.int | 2026-10-21 |
| PEPFAR budgets and expenditure | Expenditure account | 32 | 8 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR results by funding agency | Programme record | 29 | 4 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| Global Fund Data Service | Programme record | 21 | 5 | 2017–2025 | fetch.theglobalfund.org | 2026-10-12 |
| HIV/AIDS surveillance in Europe 2025, the joint report of ECDC (the European Centre for Disease Prevention and Control) and the WHO Regional Office for Europe, Tables 1 and 13 | Programme record | 20 | 2 | 2015–2024 | ecdc.europa.eu | 2026-10-21 |
| PEPFAR commodity procurement plans | Expenditure account | 20 | 4 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| UNAIDS Data 2025 country databook | Expenditure account | 16 | 2 | 2015–2023 | aidsinfo.unaids.org | 2026-10-15 |
| WHO HIV testing services dashboard | Programme record | 8 | 4 | 2018–2024 | eic-database-290813.ew.r.appspot.com | 2026-10-14 |
| Global Fund allocations | Expenditure account | 4 | 1 | 2017–2026 | fetch.theglobalfund.org | 2026-10-12 |
| Kazakh Scientific Centre of Dermatology and Infectious Diseases, surveys among people who inject drugs, 2022 and 2024 | Survey | 3 | 1 | 2020–2024 | kncdiz.kz | 2026-10-21 |
| PEPFAR human resources for health inventory | Expenditure account | 3 | 3 | 2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR operating-unit budgets | Expenditure account | 2 | 2 | 2020 | data.pepfar.gov | 2026-10-12 |
Indicators held
| Indicator | Domain | Unit | Rows | Years | Sources | Most recent value |
|---|---|---|---|---|---|---|
| Actual expenditure on collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $2.7m (2024) |
| Budget required for collaborative TB/HIV activities | Financing | USD | 7 | 2018–2024 | WHO Global Tuberculosis Programme | $2.7m (2024) |
| Country-reported HIV expenditure, all sources | Financing | USD | 19 | 2012–2024 | UNAIDS AIDSinfo, UNAIDS Global AIDS Monitoring expenditure database | $65.5m (2024) |
| Domestic funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $105.7m (2024) |
| Domestic public HIV expenditure | Financing | USD | 16 | 2015–2024 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $61.6m (2024) |
| Expected Global Fund funding for the national TB programme | Financing | USD | 7 | 2018–2024 | WHO Global Tuberculosis Programme | $2.8m (2024) |
| Expected USAID funding for the national TB programme | Financing | USD | 6 | 2018–2024 | WHO Global Tuberculosis Programme | $0 (2024) |
| Expected domestic funding for the national TB programme | Financing | USD | 7 | 2018–2024 | WHO Global Tuberculosis Programme | $129.6m (2024) |
| Expected funding for collaborative TB/HIV activities | Financing | USD | 7 | 2018–2024 | WHO Global Tuberculosis Programme | $2.7m (2024) |
| External HIV financing (all donors, ODA) | Financing | USD | 23 | 2002–2024 | OECD Creditor Reporting System | $4.6m (2024) |
| External HIV financing from governments other than the United States (IATI) | Financing | USD | 7 | 2003–2009 | IATI, through d-portal | $-171 (2009) |
| External HIV financing from multilateral bodies other than the Global Fund (IATI) | Financing | USD | 15 | 2012–2026 | IATI, through d-portal | $69k (2026) |
| External HIV financing from the United States (ODA) | Financing | USD | 46 | 2003–2026 | ForeignAssistance.gov, OECD Creditor Reporting System | $680k (2026) |
| Funding received for collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $2.7m (2024) |
| Global Fund HIV allocation for a whole three-year cycle, not an annual figure | Financing | USD per three-year allocation cycle | 4 | 2017–2026 | Global Fund allocations | 4,961,388 (2026) |
| Global Fund HIV disbursements to the country | Financing | USD | 54 | 2003–2026 | IATI, through d-portal, OECD Creditor Reporting System, UNAIDS Global AIDS Monitoring expenditure database | $1.3m (2026) |
| Global Fund funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $2.7m (2024) |
| HIV spending on TB/HIV co-infection | Financing | USD | 7 | 2016–2024 | UNAIDS Global AIDS Monitoring expenditure database | $18k (2024) |
| HIV spending on community mobilisation and system strengthening | Financing | USD | 6 | 2017–2024 | UNAIDS Global AIDS Monitoring expenditure database | $565k (2024) |
| HIV spending on critical enablers | Financing | USD | 9 | 2016–2024 | UNAIDS Global AIDS Monitoring expenditure database | $241k (2024) |
| HIV spending on gender programmes | Financing | USD | 2 | 2023–2024 | UNAIDS Global AIDS Monitoring expenditure database | $304k (2024) |
| HIV spending on governance and sustainability | Financing | USD | 9 | 2016–2024 | UNAIDS Global AIDS Monitoring expenditure database | $24.0m (2024) |
| HIV spending on prevention | Financing | USD | 9 | 2016–2024 | UNAIDS Global AIDS Monitoring expenditure database | $5.1m (2024) |
| HIV spending on prevention of vertical transmission | Financing | USD | 7 | 2016–2024 | UNAIDS Global AIDS Monitoring expenditure database | $381k (2024) |
| HIV spending on programmes for children and adolescents | Financing | USD | 3 | 2019–2024 | UNAIDS Global AIDS Monitoring expenditure database | $156k (2024) |
| HIV spending on social protection and economic support | Financing | USD | 6 | 2017–2024 | UNAIDS Global AIDS Monitoring expenditure database | $375k (2024) |
| HIV spending on treatment, care and support | Financing | USD | 9 | 2016–2024 | UNAIDS Global AIDS Monitoring expenditure database | $34.4m (2024) |
| International HIV expenditure (country-reported) | Financing | USD | 18 | 2015–2024 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $3.9m (2024) |
| Other bilateral HIV expenditure (country-reported) | Financing | USD | 1 | 2023 | UNAIDS Global AIDS Monitoring expenditure database | $935k (2023) |
| PEPFAR expenditure, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $779k (2025) |
| PEPFAR expenditure, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $845k (2025) |
| PEPFAR expenditure, all US agencies | Financing | USD | 16 | 2015–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets, UNAIDS Global AIDS Monitoring expenditure database | $1.6m (2025) |
| PEPFAR expenditure, other US agencies | Financing | USD | 1 | 2021 | PEPFAR budgets and expenditure | $0 (2021) |
| PEPFAR planned commodity procurement, like for like | Financing | USD | 5 | 2021–2025 | PEPFAR commodity procurement plans | $52k (2025) |
| PEPFAR planned funding (budget), all US agencies | Financing | USD | 6 | 2020–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets | $3.7m (2025) |
| PEPFAR planned funding, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $1.8m (2025) |
| PEPFAR planned funding, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $1.9m (2025) |
| PEPFAR planned funding, other US agencies | Financing | USD | 1 | 2021 | PEPFAR budgets and expenditure | $160k (2021) |
| PEPFAR planned procurement of antiretroviral drugs | Financing | USD | 5 | 2021–2025 | PEPFAR commodity procurement plans | $0 (2025) |
| PEPFAR planned procurement of laboratory commodities | Financing | USD | 5 | 2021–2025 | PEPFAR commodity procurement plans | $0 (2025) |
| PEPFAR planned procurement of rapid test kits | Financing | USD | 5 | 2021–2025 | PEPFAR commodity procurement plans | $52k (2025) |
| PEPFAR spend on staff, human resources for health inventory | Financing | USD | 1 | 2025 | PEPFAR human resources for health inventory | $1.0m (2025) |
| PEPFAR-funded staff delivering services, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 19 (2025) |
| PEPFAR-funded staff, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 53 (2025) |
| US HIV disbursements managed by Health and Human Services | Financing | USD | 7 | 2020–2026 | ForeignAssistance.gov | $160k (2026) |
| US HIV disbursements managed by USAID | Financing | USD | 24 | 2003–2026 | ForeignAssistance.gov | $-5 (2026) |
| US HIV disbursements managed by other US agencies | Financing | USD | 8 | 2005–2014 | ForeignAssistance.gov | $0 (2014) |
| US HIV disbursements managed by the State Department | Financing | USD | 5 | 2021–2026 | ForeignAssistance.gov | $521k (2026) |
| USAID funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $0 (2024) |
| % of ALL PLHIV who are virally suppressed | Treatment cascade | percent | 26 | 2010–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 75.0% (2025) |
| % of PLHIV on ART (second 95, PLHIV base) | Treatment cascade | percent | 70 | 2000–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 79.0% (2025) |
| % of PLHIV who have been diagnosed (first 95) | Treatment cascade | percent | 29 | 2010–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 85.0% (2025) |
| % of estimated HIV-positive incident TB cases on TB treatment and ART | Treatment cascade | percent | 21 | 2003–2024 | UNAIDS AIDSinfo | 84.5% (2024) |
| % of people currently enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 7 | 2018–2024 | UNAIDS AIDSinfo | 10.3% (2024) |
| % of people living with HIV on ART who completed a course of TB preventive therapy | Treatment cascade | percent | 4 | 2019–2024 | UNAIDS AIDSinfo | 99.3% (2024) |
| % of people newly enrolled in HIV treatment diagnosed with TB disease | Treatment cascade | percent | 12 | 2013–2024 | UNAIDS AIDSinfo | 4.9% (2024) |
| % of people newly enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 12 | 2013–2024 | UNAIDS AIDSinfo | 73.8% (2024) |
| % of people on ART who are virally suppressed (third 95) | Treatment cascade | percent | 29 | 2015–2025 | PEPFAR results by province, WHO Global Health Observatory | 95.0% (2025) |
| % of returned HIV test results that were positive | Treatment cascade | percent | 9 | 2018–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 0.1% (2024) |
| HIV self-test kits distributed | Treatment cascade | count | 1 | 2024 | WHO HIV testing services dashboard | 15,295 (2024) |
| HIV tests performed at a health facility | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality, WHO HIV testing services dashboard | 206 (2025) |
| HIV tests performed through community outreach | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 17 (2025) |
| HIV tests performed with the result returned to the person | Treatment cascade | count | 46 | 2016–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 223 (2025) |
| HIV-exposed infants tested within two months of birth | Treatment cascade | percent | 15 | 2010–2024 | UNAIDS AIDSinfo | 76.0% (2024) |
| HIV-positive TB patients started or continued on ART | Treatment cascade | count | 10 | 2015–2024 | WHO Global Tuberculosis Programme | 448 (2024) |
| Key-population people tested for HIV (count over the period) | Treatment cascade | count | 6 | 2024–2025 | Global Fund Data Service | By population group, sex or age only, to 2025 |
| New HIV diagnoses with a CD4 count below 200 | Treatment cascade | percent | 7 | 2015–2024 | UNAIDS AIDSinfo | 3.0% (2024) |
| Newly diagnosed at HHS/CDC-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 21 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 23 (2025) |
| Newly diagnosed at USAID-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 22 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 15 (2025) |
| Newly enrolled on ART at HHS/CDC-funded partners (MER TX_NEW) | Treatment cascade | count | 24 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 300 (2025) |
| Notified HIV cases, national case surveillance | Treatment cascade | count | 30 | 2000–2024 | HIV/AIDS surveillance in Europe 2025, the joint report of ECDC (the European Centre for Disease Prevention and Control) and the WHO Regional Office for Europe, Tables 1 and 13, WHO Europe Health for All database | 3,999 (2024) |
| Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS) | Treatment cascade | count | 36 | 2016–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality | 38 (2025) |
| Number of PLHIV virally suppressed (VL<1000) | Treatment cascade | count | 26 | 2017–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province | 11,004 (2025) |
| Number of people on ART (PEPFAR MER TX_CURR) | Treatment cascade | count | 101 | 2000–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO Global Tuberculosis Programme | 34,191 (2025) |
| People newly diagnosed at a health facility | Treatment cascade | count | 7 | 2018–2025 | PEPFAR testing by modality | 23 (2025) |
| People newly diagnosed through community outreach | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 15 (2025) |
| People newly enrolled on ART during the year | Treatment cascade | count | 40 | 2013–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province, WHO Global Tuberculosis Programme | 300 (2025) |
| People on ART at HHS/CDC-funded partners (MER TX_CURR) | Treatment cascade | count | 24 | 2018–2025 | PEPFAR results by funding agency, PEPFAR results by funding agency and province | 12,134 (2025) |
| Pregnant women tested for HIV in antenatal care | Treatment cascade | percent | 9 | 2015–2024 | UNAIDS AIDSinfo | 98.0% (2024) |
| Pregnant women with HIV who received ARVs for PMTCT | Treatment cascade | count | 16 | 2010–2025 | WHO Global Health Observatory | 437 (2025) |
| TB patients recorded as HIV-positive | Treatment cascade | count | 10 | 2015–2024 | WHO Global Tuberculosis Programme | 515 (2024) |
| TB patients with an HIV test result recorded | Treatment cascade | count | 10 | 2015–2024 | WHO Global Tuberculosis Programme | 8,956 (2024) |
| AIDS-related deaths | Epidemic estimates | count | 506 | 2000–2025 | UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 500 (2025) |
| Deaths from TB among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 51 (2024) |
| HIV prevalence among a key population | Epidemic estimates | percent | 7 | 2020–2024 | Kazakh Scientific Centre of Dermatology and Infectious Diseases, surveys among people who inject drugs, 2022 and 2024, UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| HIV prevalence, ages 15-49 | Epidemic estimates | percent | 50 | 2000–2024 | UNAIDS AIDSinfo, World Bank Open Data | 0.3% (2024) |
| Incident TB cases among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 530 (2024) |
| New HIV infections | Epidemic estimates | count | 585 | 2000–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 1,800 (2025) |
| People living with HIV | Epidemic estimates | count | 681 | 2000–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 44,000 (2025) |
| People newly reported with AIDS, national surveillance | Epidemic estimates | count | 30 | 2000–2024 | HIV/AIDS surveillance in Europe 2025, the joint report of ECDC (the European Centre for Disease Prevention and Control) and the WHO Regional Office for Europe, Tables 1 and 13, WHO Europe Health for All database | 324 (2024) |
| Key-population members reached by prevention programmes | Prevention and outreach | percent | 3 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Key-population people reached by outreach (count over the period) | Prevention and outreach | count | 7 | 2017–2025 | Global Fund Data Service | By population group, sex or age only, to 2025 |
| Male condoms distributed in a year | Prevention and outreach | count | 5 | 2019–2024 | UNAIDS AIDSinfo | 9,967,208 (2024) |
| People receiving PrEP | Prevention and outreach | count | 19 | 2021–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, UNAIDS AIDSinfo | 1,330 (2025) |
| Estimated size of a key population | Population denominators | count | 4 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Total population | Population denominators | count | 26 | 2000–2025 | World Bank Open Data | 20,843,754 (2025) |
Every row shown on the Kazakhstan page is in the panel download, with the source URL and the retrieval date of the row attached. See Data.
Turn your phone to read the chart upright